Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders
Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutionsThe company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomasTryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a…